Hepatitis C virus (HCV) is an enveloped positive-stranded RNA virus of approximately 9.6 kb that belongs to the Flaviviridae family (Suzuki et al., 2007) . HCV infection is a global health problem affecting nearly 200 million people (Lauer and Walker, 2001 ). The infection causes prolonged and persistent disease in over half of viral carriers that often leads to chronic hepatitis, cirrhosis, and hepatocellular carcinoma (Afdhal, 2004) . Recent studies have suggested that HCV infects not only hepatocytes but also peripheral mononuclear lymphocytes, particularly B cells, which express CD81, a widely expressed tetraspanin molecule. CD81 has been shown to interact with the E2 region of HCV envelope proteins (Pileri et al., 1998) and is thus regarded as one of the key molecules involved in HCV infection. HCV infection of B cells is the likely cause of various B cell dysregulation disorders. Herein, we propose that HCV uses peripheral B cells as reservoirs for persistent infection, which are in turn responsible for HCV pathogenesis.
Although the liver is considered the primary and main target of HCV infection, extrahepatic manifestations such as mixed cryoglobulinemia, a systemic immune complex-mediated disorder characterized by B cell proliferation that may evolve into overt B cell non-Hodgkin's lymphoma (B-NHL), are often recognized among patients persistently infected with HCV (Agnello et al., 1992; Zuckerman et al., 1997) . Epidemiological evidence strongly suggests a close association between chronic HCV infection and B-NHL occurrence (Turner et al., 2003; de Sanjose et al., 2008) . A pathogenic role of HCV in B cell disorders has been further demonstrated by studies in which the clinical resolution of B cell dysfunctions was observed after successful regimens of anti-HCV treatment (Mazzaro et al., 1996; Agnello et al., 2002) . Based on the aforementioned data, Antonelli et al. (2008) postulated a role of B cells in HCV pathogenesis. In accordance with this notion, our recent study clearly demonstrated papers also favored the notion of HCV lymphotropism (Ducoulombier et al., 2004; Blackard et al., 2006; Pal et al., 2006) . Figure 1 illustrates the possible process of HCV infection in B cells based on previous studies using human hepatocyte-derived cell lines (Burlone and Budkowska, 2009; Georgel et al., 2010) . Among B cell subsets, memory B cells are assumed to be the main reservoirs of HCV infection primarily because of their long lifespans. In support of this notion, our recent study indicated that CD19 + CD27 + cells (i.e., memory B cell phenotype) express a high amount of CXCR3, a chemokine receptor, and are recruited to the inflammatory site in the liver of CHC patients where IFN-γ-inducible protein-10, a CXCR3 ligand, is highly produced (Mizuochi et al., 2010 ; Figure 1 ). This unique strategy seems to that HCV infects and may replicate in the peripheral CD19
+ B cells of chronic hepatitis C (CHC) patients (Ito et al., 2010a) . In order to determine how HCV evades antiviral innate immune responses that are normally induced in B cells, we analyzed expression levels of IFN-β in peripheral B cells of CHC patients because type I IFN plays a critical role in the antiviral innate immune response. We found that HCV infection failed to trigger antiviral immune responses, such as IFN-β production, in B cells of CHC patients (Ito et al., 2010b) . This suggests that HCV evades antiviral innate immune responses in peripheral B cells and uses these cells as reservoirs for its persistent infection in the host.
The idea that B cells may serve as HCV reservoirs was advocated by Muller et al. (1993) . Several subsequently published be beneficial for HCV in securing sites for persistent infection. HCV may search for reservoir sites in cellular compartments other than hepatocytes in case the liver becomes unsuitable for HCV replication, perhaps because of cellular destruction caused by the host immune response and/ or by irrelevant conditions for successful virus replication, such as the development of cirrhosis or hepatocellular carcinoma.
Peripheral B cells as reservoirs for persistent HCV infection
At least two important issues remain to be investigated. First, how do HCV-infected B cells evade "acquired/adaptive" immune responses represented by cytotoxic T cells (CTL)? In peripheral blood, the frequencies of HCV-specific CD8
+ lymphocytes with persistent HCV infection are lower than those with acute HCV infection. Furthermore, the CTL response to the HCV antigen is impaired in chronic HCV patients (Lechner et al., 2000) . Interestingly, the percentage of CTL in peripheral blood is lower than that in the liver, which may be advantageous for persistent HCV infection in B cells. Because the peripheral B cells of CHC patients express the HCV core as well as NS3 antigens (Ito et al., 2010a) , both of which encode functional CTL epitopes (Hiroishi et al., 2010) , it is possible that HCV-infected B cells are eliminated by CTL to some extent. However, the fact that substantial amounts of HCV-infected B cells are found in CHC patients suggests incomplete elimination by CTL by an inhibitory mechanism, i.e., HCV E2-mediated inhibition of IL-2/IFN-γ secretion (Petrovic et al., 2011) . Second, do HCV-infected B cells produce infectious HCV? Stamataki et al. (2009) demonstrated that the infectious JFH-1 strain of HCV can bind B cells but fails to establish productive infection. On the other hand, Inokuchi et al. (2009) recently demonstrated the presence of negative-stranded HCV RNA, a marker of viral replication, in B cells from 4 of 75 (5%) CHC patients. These results support the notion that HCV replicates in B cells and suggest that infectious HCV are produced in B cells. We have currently been investigating this intriguing issue by using an in vitro assay system.
In conclusion, lymphoid reservoirs of HCV infection may play a role in viral persistence and thereby be involved in its pathogenesis. Infection and replication of HCV in peripheral B cells should be regarded as a considerable impediment to the treatment of CHC patients undergoing various antiviral regimens. From a therapeutic viewpoint, it may be beneficial to eliminate peripheral B cells in CHC patients by administering anti-B cell antibodies, such as rituximab, along with combination chemotherapy of peg-IFN-α and ribavirin, which eliminate circulating HCV in the blood. Together, this could lead to a synergistic effect on HCV clearance in CHC patients.
